Medpace Holdings, Inc. MEDP Oncology — Total Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Medpace Holdings, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Medpace Holdings, Inc.’s 10-Q, filed April 23, 2026, on SEC EDGAR. View the filing →
Ask your AI about Medpace Holdings, Inc.'s oncology — total revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Medpace Holdings, Inc.'s oncology — total revenue?
- Medpace Holdings, Inc. (MEDP) reported oncology — total revenue of $237.56M in Q1 2026.
- How has Medpace Holdings, Inc.'s oncology — total revenue changed year-over-year?
- Medpace Holdings, Inc.'s oncology — total revenue increased by 60.5% year-over-year, from $148.02M to $237.56M.
- What is the long-term trend for Medpace Holdings, Inc.'s oncology — total revenue?
- Over 4 years (2021 to 2025), Medpace Holdings, Inc.'s oncology — total revenue has grown at a 46.9% compound annual growth rate (CAGR), from $159.9M to $744.96M.
- What does oncology — total revenue mean?
- The total revenue earned from providing clinical trial and drug development services for oncology-related projects.
- How do you interpret oncology — total revenue?
- An increase indicates growing demand for the company's specialized oncology research services and successful project acquisition within the cancer therapeutic space. A decrease may signal a loss of market share, reduced client R&D spending in oncology, or the completion of large-scale clinical trials without sufficient replacement projects.
- How does oncology — total revenue compare across companies?
- Comparable to oncology-specific revenue streams reported by other contract research organizations (CROs) or specialized clinical trial service providers, often benchmarked against broader industry R&D spending trends in oncology.